Aptamers: A New Technological Platform in Cancer Immunotherapy
The renaissance of cancer immunotherapy is, nowadays, a reality. In the near future, it will be very likely among the first-line treatments for cancer patients. There are several different approaches to modulate the immune system to fight against tumor maladies but, so far, monoclonal antibodies may...
Main Author: | Fernando Pastor |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-10-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | http://www.mdpi.com/1424-8247/9/4/64 |
Similar Items
-
CD28 Aptamers as Powerful Immune Response Modulators
by: Fernando Pastor, et al.
Published: (2013-01-01) -
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
by: George Fromm, et al.
Published: (2018-12-01) -
Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles
by: Xialian Lai, et al.
Published: (2023-03-01) -
Dual Checkpoint Aptamer Immunotherapy: Unveiling Tailored Cancer Treatment Targeting CTLA-4 and NKG2A
by: Mohamad Ammar Ayass, et al.
Published: (2024-03-01) -
Aptamer-Based Strategies to Boost Immunotherapy in TNBC
by: Lisa Agnello, et al.
Published: (2023-03-01)